scispace - formally typeset
S

Sherif F. Hammad

Researcher at Helwan University

Publications -  31
Citations -  208

Sherif F. Hammad is an academic researcher from Helwan University. The author has contributed to research in topics: Medicine & Chemistry. The author has an hindex of 7, co-authored 16 publications receiving 98 citations. Previous affiliations of Sherif F. Hammad include Egypt-Japan University of Science and Technology.

Papers
More filters
Journal ArticleDOI

Antiviral Nucleoside and Nucleotide Analogs: A Review

TL;DR: This review summarizes the antiviral activity of nucleoside and nucleotide analogs and their recent application.
Journal ArticleDOI

Synthesis and in vitro anticancer evaluation of some fused indazoles, quinazolines and quinolines as potential EGFR inhibitors.

TL;DR: Both compounds 15c and 19b did not display any significant cytotoxicity towards normal BHK-21 fibroblast cells (IC50 value > 200 µM), thereby providing a good safety profile as anticancer agents.
Journal ArticleDOI

Generation of a cell-permeable cycloheptapeptidyl inhibitor against the peptidyl-prolyl isomerase Pin1.

TL;DR: It is shown that it is possible to design a cell-permeable and biologically active cycloheptapeptide inhibitor against the intracellular enzyme peptidyl-prolyl isomerase Pin1 by integrating cell-penetrating and target-binding sequences.
Journal ArticleDOI

Anti-Inflammatory and Anti-Hyperuricemic Functions of Two Synthetic Hybrid Drugs with Dual Biological Active Sites

TL;DR: Interestingly, both compounds were potent xanthine oxidase inhibitors as well as Cox inhibitors with higher activity in favor of compound B providing potential dual acting series of anti-hyperuricemic and anti-inflammatory therapeutic agents.
Journal ArticleDOI

Sofosbuvir Thio-analogues: Synthesis and Antiviral Evaluation of the First Novel Pyridine- and Pyrimidine-Based Thioglycoside Phosphoramidates

TL;DR: Eight compounds were evaluated for their antiviral activities against different viral cell lines, namely, adenovirus 7, HAV (hepatitis A) HM175, Coxsackievirus B4, and HSV-1 (herpes simplex virus type 1), in addition to the antiviral bioassay against ED-43/SG-Feo (VYG) replicon of HCV ( hepatitis C virus) genotype 4a.